Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-16
2010-02-23
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S400000
Reexamination Certificate
active
07666902
ABSTRACT:
The subject invention provides anticoagulant compounds of formula I:and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.
REFERENCES:
patent: 5510375 (1996-04-01), Domagala et al.
patent: 5686486 (1997-11-01), Tomich et al.
patent: 6864279 (2005-03-01), Druzgala et al.
patent: 2004/0058985 (2004-03-01), Carter
patent: 2004/0220258 (2004-11-01), Druzgala et al.
patent: 02/085882 (2002-10-01), None
patent: 2004/058985 (2004-03-01), None
Theopold et. al. “Coagulation in arthropods: defence, wound closure and healing.” Trends in Immunology 2004, 25(6), 289.
McMaster Hematology program Online “http://fhs.mcmaster.ca/hemares/designduration.htm” accessed Oct. 17, 2008.
Oldenburg, J. et. al. Chapter 3 “The Vitamin K Cycle” in Vitamins and Hormones, 2008, vol. 78, 35-62.
Mann et. al. “Biochemistry and Physiology of Blood Coagulation” Thrombosis and Haemostasis 1999, 82(2) 165-174.
“Coumadin Tablets” Online “http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf” accessed Oct. 20, 2008.
Alan T. Nurden “Inherited disorders of platelets: an update” Current Opinion in Hematology 2006, 13:157-162.
Dahl et. al. Bioorganic Chemistry 1981, 10, 329-341.
Castro et. al. Journal of Agricultural & Food Chemistry 1988, 36, 915-919.
Wheeler, et. al. Chemical Research in Toxicology 2001, 14, 1107-1117.
Leo Goodstadt and Chris P. Ponting “Vitamin K epoxide reductase: homology, active site and catalytic mechanism” Trends in Biochemical Sciences 2004, 29 (6), 289-292.
Johnson, A. W. Invitation to Organic Chemistry 1999 Jones and Bartlett: Mississauga, Canada, p. 24.
Horton, Robert H. et. al. Methods in Enzymology 1967, 11, 556-565.
Tou et. al. Analytical Chemistry 1974, 46, 1866-1869.
Jones et. al. Journal of the American Chemical Society 1967, 89, 4863-4867.
Online “http://www.auburn.edu/˜deruija/pda1—resonance.pdr” accessed Jun. 22, 2009.
Becker Cyrus
Druzgala Pascal
ARYx Therapeutics, Inc.
Desai Rita J
McDonnell Boehnen & Hulbert & Berghoff LLP
O'Dell David K
LandOfFree
Haloalkyl ester derivatives of coumarin for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Haloalkyl ester derivatives of coumarin for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Haloalkyl ester derivatives of coumarin for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177763